Breaking Finance News

Raymond James downgraded QuintilesIMS (NYSE:Q) from Strong Buy to Mkt Perform in a report released today.

Raymond James has downgraded QuintilesIMS (NYSE:Q) from Strong Buy to Mkt Perform in a report released on Thursday December 01, 2016.

Previously on 11/30/2016, Barclays Capital reported about QuintilesIMS (NYSE:Q) raised the target price from $0.00 to $90.00. At the time, this indicated a possible upside of 0.15%.

Yesterday QuintilesIMS (NYSE:Q) traded -5.07% lower at $76.83. The company’s 50-day moving average is $76.07 and its 200-day moving average is $73.55. The last stock close price is up 4.47% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 4,811,134 shares of the stock were exchanged, up from an average trading volume of 1,384,210

See Chart Below

QuintilesIMS (NYSE:Q)

QuintilesIMS has a 52 week low of $55.01 and a 52 week high of $81.45 with a P/E ratio of 23.63 The company’s market cap is currently $0.

In addition to Raymond James reporting its target price, a total of 15 firms have reported on the stock. The consensus target price is $76.50 with 8 firms rating the stock a strong buy, 9 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About QuintilesIMS (NYSE:Q)

Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.